SwanBio Therapeutics

SwanBio Therapeutics is dedicated to pioneering biotechnology research, focusing on the development of innovative gene therapies. With a commitment to delivering dramatic clinical efficacy, SwanBio Therapeutics is advancing the field of neurological disease treatment. SwanBio Therapeutics' research is geared toward creating breakthroughs that improve patient outcomes and transform lives.

Located at 150 Monument Rd, Suite 207, Bala Cynwyd, Pennsylvania 19004, US, with an additional location at 245 Main Street, 2nd Fl, Cambridge, Massachusetts 02142, US, SwanBio Therapeutics is strategically positioned to leverage cutting-edge research and development. SwanBio Therapeutics continues to expand its capabilities and explore new frontiers in genetic medicine.

SwanBio Therapeutics is now part of Spur Therapeutics, and is committed to innovation and excellence in biotechnology. The company's potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. We invite the management team at SwanBio Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight your achievements and capabilities.